BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Thursday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other research analysts have also recently weighed in on the stock. Ascendiant Capital Markets reduced their price target on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Price Performance

BIOLASE stock opened at $0.01 on Thursday. The stock has a market capitalization of $167,035.00, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94. The company has a 50 day moving average of $0.02 and a 200-day moving average of $0.07.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC increased its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.79% of the company’s stock.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.